|Home||Company Search||Related Articles||Forum (new!)|
|Company||GlaxoSmithKline [Company Info]|
|Track this Company (an email will be sent to you everytime a report is filed about this company)|
|18th Mar 2005||Other Issue||Glaxo shares dip on factory probe|
|GlaxoSmithKline shares have fallen almost 2% amid fears a US inquiry into manufacturing quality could be widened and may possibly lead to a big fine.
On 4 March the US Food and Drug Administration (FDA) seized batches of two drugs from the Puerto Rico plant.
Regulators said its diabetes treatment Avandamet and anti-depressant Paxil CR tablets failed to meet safety standards - but did not pose a health risk.
Glaxo could face a fine of as much as $1.4bn (£730m), Reuters reported.
Such a penalty could be imposed if the FDA obtains a formal order requiring Glaxo to resolve issues at the Cidra factory, said analyst Michael Leacock at Nomura.
The FDA action could see all manufacturing at the plant halted although regulators might permit production of other treatments to continue while its inquiry continued.
Glaxo spokesman Phil Thomson said the company had not yet discussed such an order with the FDA.
Shares in Glaxo were trading down 1.84% at 1224 pence by the close of trade on Friday. Its stock has fallen almost 10% since the FDA seizure on 4 March.
|Other Reports on GlaxoSmithKline|
|29th Jan 2007||Questionable Practice||GlaxoSmithKline||GSK hid paxil suicide link|
|10th Aug 2006||Other Issue||GlaxoSmithKline||Glaxo pays $70m to end price row|
|29th Mar 2006||Questionable Practice||GlaxoSmithKline||Glaxo agrees US Paxil settlement|
|22nd Sep 2004||Questionable Practice||GlaxoSmithKline||Glaxo drops appeal in Aids drug pricing case|
|6th Sep 2004||Other Issue||GlaxoSmithKline||GSK faces anti-depressant lawsuit|
|19th May 2004||Other Issue||GlaxoSmithKline||New York sues GlaxoSmithKline|
|11th May 2004||Fraud Investigation||GlaxoSmithKline||GlaxoSmithKline faces antitrust investigation|
|22nd Jan 2004||Fraud Investigation||GlaxoSmithKline||$11.1 Million settlement|
|8th Jan 2004||Questionable Practice||GlaxoSmithKline||£1.5bn Tax Bill|
|16th Dec 2003||Questionable Practice||GlaxoSmithKline||Glaxo's CEO to scoop 5.7 mln stg a year|
|25th Jun 2003||Questionable Practice||GlaxoSmithKline||FDA tells Glaxo to pull misleading Flonase ads|
|25th Jun 2003||Questionable Practice||GlaxoSmithKline||Ordered to pull misleading adverts|
|Related Reports from the Pharamaceutical Industry|
|Pfizer||Questionable Practice||State Tax Report|
|Merck||Other Issue||Vioxx drug ban hits Merck profits|
|Bristol-Myers Squibb||Questionable Practice||Bristol-Myers to pay $515m fine|
|Merck||Other Issue||Merck denies heart attack claim|
|Pfizer||Other Issue||Nigeria files new Pfizer claims|
|© 2006 Corp-Ethics.com | Corporate Ethics|